Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.

Quil-A® Literature

Recommended reading about Quil-A® ADJUVANTS:

Leenaars, P.P.A.M.; Hendriksen, C.F.M.; de Leeuw, W.A.; Carat, F.; Delahaut, P.; Fischer, R.; Halder, M.; Hanley, W.C.; Hartinger, J.; Hau, J.; Lindblad, E.B.; Nicklas, W.; Outschoorn, I.M. and Stewart-Tull, D.E.S. (1999).
The Production of Polyclonal Antibodies in Laboratory Animals. The Report and Recommendations of ECVAM/FELASA Workshop 35.
ATLA 27: 70-102.

Williams WV, Kyriako sM, Sharp GC, Braley-Mullen H. (1987).
Effects of the ADJUVANTS SGP and Quil A on the induction of experimental autoimmune thyroiditis in mice.
CellImmunol. 104(2):296-303.

Vanselow BA, Abetz I, Trenfield K. (1985).
A bovine ephemeral fever vaccine incorporating ADJUVANT Quil A: a comparative study using ADJUVANTS Quil A, aluminium hydroxide gel and dextransulphate.
VetRec. 117(2):37-43.

Flebbe LM, Braley-Mullen H. (1986).
Immunopotentiating effects of the ADJUVANTS SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens.
CellImmunol. 99(1):119-27.

Flebbe LM, Braley-Mullen H. (1986).
Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations.
Cell Immunol. 15;99(1):128-39.

Verheul AF, Versteeg AA, De Reuver MJ, Jansze M, Snippe H. (1989).
Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the ADJUVANT Quil A depends
InfectImmun. 57(4):1078-83

Lindblad, E.B. (2007)
Safety Evaluation of Vaccine ADJUVANTS. Chapter 18 in: Vaccine ADJUVANTs and Delivery Systems.
Ed. M. Singh : p 421-444.
John Wiley & Sons Publishers .

Dalsgaard K. (1984).
Assessment of the dose of the immunological ADJUVANT Quil A in mice and guinea pigs, using sheep red blood cells as model antigen.
ZentralblVeterinarmedB. 31(9):718-20.

Dalsgaard K, Jensen MH. (1977)
Saponin ADJUVANTS. VI. The ADJUVANT activity of quil A in trivalent vaccination of cattle and guinea pigs against foot-and-mouth disease.
Acta VetScand. 18(3):367-73.

Dalsgaard K, Jensen MH, SorensenKJ. (1977).
Saponin ADJUVANTS. IV. Evaluation of the ADJUVANT quil A in the vaccination of cattle against foot-and-mouth disease.
Acta VetScand. 18(3):349-60.

Chavali SR, Francis T, Campbell JB. (1987).
An in vitro study of immunomodulatory effects of some saponins.
IntJ Immunopharmacol.9(6):675-83.

Verheul AF, Poolman JT, Snippe H, VerhoefJ. (1991).
The influence of the ADJUVANT Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies.
Mol Immunol. 28(11):1193-200.

Mowat AM, Donachie AM, Reid G, Jarrett O. (1991).
Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.
Immunology. 1991 72(3):317-22.

Oosterlaken TA, Brandenburg A, Schielen P, Fransen R, Kraaijeveld CA, Snippe H. (1991).
Efficient induction of Semliki Forest virus and mumps virus neutralizing anti-anti-idiotypicantibodies using Quil A as ADJUVANT.
J ImmunolMethods. 136(2):169-75.

DeVelasco EA, Dekker HA, Antal P, Jalink KP, van Strijp JA, Verheul AF, Verhoe fJ, Snippe H. (1994).
ADJUVANT Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines.
Vaccine. 12(15):1419-22.

Jackson LA, Opdebeeck JP. (1994)
Quil A and ISCOMs as ADJUVANTS for midgut membrane antigens of Boophilusmicroplus.
ApplParasitol. 35(2):87-98.

Lipford GB, Lehn N, Bauer S, Heeg K, Wagner H. (1994)
The immunodominant peptide from listeriolysinin Quil A liposomes vaccinates CD8+ cytolyticT cells and confers protection to infection.
ImmunolLett. 40(2):101-4.

Lipford GB, Wagner H, Heeg K. (1994)
Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells.
Vaccine. 12(1):73-80.

White K, Rades T, Kearns P, Toth I, Hook S. (2006)
Immunogenicity of liposomescontaining lipid core peptides and the ADJUVANT Quil A.
PharmRes.23(7):1473-81.

Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T.(2006).
On the preparation, microscopic investigation and application of ISCOMs.
Micron. 37(8):724-34.

Pham HL, Shaw PN, Davies NM.(2006).
Preparation of immuno-stimulating complexes (ISCOMs) by ether injection.
IntJ Pharm. 310(1-2):196-202.

Pham HL, Ross BP, McGeary RP, Shaw PN, Hewavitharana AK, Davies NM. (2006).
Saponins from Quillaja saponaria Molina: isolation, characterization and ability to form immunostimulatory complexes (ISCOMs).
CurrDrug Deliv. 3(4):389-97.

Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, Agadjanyan MG. (2006).
Prototype Alzheimer’s disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A ADJUVANT switch.
Vaccine. 24(13):2275-82.

Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. (2006).
Modulating the ADJUVANTicity of alum by co-administration of muramyldi-peptide (MDP) or Quil-A.
Vaccine. 24(8):1081-6.

Content